Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.38 |
| ▸ | CDK2 | P24941 | 5/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.31 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24572410 | 0.82 | CCNE1 (0.49) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL627862 | 0.71 | CCNE1 (0.46) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL16266936 | 0.71 | ALDH1A1 (0.39) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL5781198 | 0.68 | CCNE1 (0.46) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL16742529 | 0.68 | NPC1 (0.33) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL28112274 | 0.67 | CCNE1 (0.37) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL628287 | 0.66 | GSK3B (0.37) | ESR2 | |
| SCHEMBL24923989 | 0.65 | — | — | |
| SCHEMBL26672257 | 0.64 | — | — | |
| SCHEMBL24572407 | 0.63 | CCNE1 (0.45) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419417-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-25 | — | — | EP | disclosed |
| EP-2419417-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-25 | — | — | EP | disclosed |
| CN-102459225-B | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2 | JANSSEN PHARMACEUTICA NV | 2014-08-20 | — | — | CN | disclosed |
| US-8269015-B2 | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-18 | — | — | US | disclosed |
| US-8269015-B2 | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-18 | — | — | US | disclosed |
| US-8269015-B2 | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-18 | — | — | US | disclosed |
| CN-102459225-A | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2 | JANSSEN PHARMACEUTICA NV | 2012-05-16 | — | — | CN | disclosed |
| EP-2419417-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010121011-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010121011-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | ESR2 567/4885CCNE1 885/4885CDK2 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.